.png)
1 week ago
4
Biogen (BIIB) banal was muted Thursday aft the biotech institution bushed Wall Street's first-quarter expectations, including beardown income for newcomer drugs Leqembi and Skyclarys.
Leqembi, which spouse Eisai (ESAIY) records, generated $96 cardinal successful sales, continuing a inclination of sequential growth. Skyclarys brought successful $124 cardinal successful sales, increasing astir 59% twelvemonth implicit year. Biogen acquired the Friedreich's ataxia cause successful the 2023 takeover of Reata Pharmaceuticals.
↑ X NOW PLAYING Tariffs Take Toll On Tech Giants. Will Earnings Reveal The Damage?
Neither cause belongs to Biogen's aggregate sclerosis franchise. The part is Biogen's biggest, but is nether unit from generic rivals. Sales skidded 11% to $953 million. In changeless currency, aggregate sclerosis cause income fell 10%. Still, income of cardinal MS drugs Tysabri and Tecfidera bushed expectations.
Tysabri and Tecfidera's holding up is "reassuring successful our presumption successful airy of expected declines implicit clip for these franchises," RBC Capital Markets expert Brian Abrahams said successful a report. He noted it's "unclear if determination were circumstantial inventory effects contributing."
Biogen banal was level astatine 121.05 successful premarket action. Shares fell beneath their 50-day moving mean successful mid-March.
Biogen Stock: Sales, Earnings Beat
Across each products, income climbed 6% — oregon 8% successful changeless currency — to $2.43 billion. That bushed expectations for $2.23 billion, according to FactSet. Biogen earned an adjusted $3.02 per share. Though net sank 18% twelvemonth implicit year, they topped the Street's forecast for $2.92.
The champion maturation came from Biogen's uncommon diseases portfolio, which surged 33% to $563 million. That part includes Skyclarys and spinal muscular atrophy cause Spinraza. Spinraza income jumped much than 24% to $424 million, handily supra projections for $361 million.
Biosimilar sales, though, slipped northbound of 8% to astir $181 million.
Still, Abrahams kept his outperform standing and 217 terms people connected Biogen stock, questioning whether this is "the commencement of a turnaround."
'Significant' Manufacturing In The U.S.
For the year, Biogen chopped its net expectations to $14.50 to $15.50 per share, minus immoderate items.
That includes a 95-cent deed owed to a precocious inked collaboration woody with Stoke Therapeutics (STOK) to make a attraction for a uncommon signifier of epilepsy known arsenic Dravet syndrome. As portion of that deal, Biogen volition wage Stoke $165 cardinal up front. The midpoint of Biogen's net guidance missed analysts' telephone for $15.21.
Biogen besides expects full-year income to diminution by a mid single-digit percentage, excluding the interaction of speech rates. The institution noted it doesn't expects tariffs to person an outsized interaction connected its fiscal metrics. The institution has a "significant manufacturing beingness successful the U.S.," Viehbacher said.
"Roughly 75% of our 2024 U.S. merchandise revenues were generated by products which person manufacturing operations successful the U.S.," helium said. "In addition, Biogen pays important taxes successful the U.S. since our U.S. marketplace revenues are astir wholly taxable successful the U.S. astatine Federal and authorities taxation rates."
Follow Allison Gatlin connected X/Twitter astatine @AGatlin_IBD.
YOU MAY ALSO LIKE:
Hims Stock Catapults After Inking Deal To Sell Novo Nordisk's Wegovy
IBD 50's GeneDx, Down 43%, Was 'Priced For Perfection.' Here's What It Missed.
IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks
Looking For The Next Apple Or Amazon? Start With These S&P 500-Beating Lists
English (US) ·